Skip to main content

Table 4 Adverse events due to chemotherapy according to tomographic response to neoadjuvant chemotherapy (n = 53). Percentage values are calculated within groups

From: Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer

Adverse event (CTCAE 5.0) With response (%) Without response (%) p-valuea
Neutropenia Grade 0 10 (31.3) 4 (19.0) 0.582
Grade 1 1 (3.1) 2 (9.52)
Grade 2 8 (25.0) 8 (38.1)
Grade 3 11 (34.4) 5 (23.9)
Grade 4 2 (6.3) 2 (9.5)
Anemia Grade 0 19 (35.8) 12 (22.6) 0.773
Grade 1 5 (9.4) 2 (3.8)
Grade 2 7 (13.2) 5 (9.4)
Grade 3 1 (1.9) 2 (3.8)
Thrombocytopenia Grade 0 29 (90.6) 15 (71.42) 0.134
Grade 1 2 (6.2) 1 (4.8)
Grade 2 0 (0.0) 3 (14.3)
Grade 3 1 (3.1) 2 (9.5)
Nausea Grade 0 19 (57.6) 11 (52.4) 0.953
Grade 1 9 (27.3) 7 (33.3)
Grade 2 4 (12.1) 3 (14.3)
Grade 3 1 (3.0) 0 (0.0)
Emesis Grade 0 26 (81.2) 15 (71.4) 0.676
Grade 1 4 (12.5) 5 (23.8)
Grade 2 2 (6.3) 1 (4.8)
Diarrhea Grade 0 27 (84.4) 20 (95.2) 0.781
Grade 1 4 (12.5) 1 (4.8)
Grade 2 1 (3.1) 0 (0.0)
Renal toxicity Yes 1 (3.1) 0 (0.0) 1
No 31 (96.9) 21 (100.0)
Liver Toxicity Yes 1 (3.1) 0 (0.0) 0.413
No 31 (96.9) 21 (100.0)
Peripheral Grade 0 23 (71.9) 14 (66.7) 0.908
Neuropathy Grade 1 5 (15.6) 3 (14.3)
Grade 2 4 (12.5) 4 (19.0)
  1. a Fisher exact test; CTCAE 5.0: Common Terminology Criteria for Adverse Events version 5.0